2025-06-30　恭賀邱仁祥醫檢師當選『第17屆南投縣醫檢師公會理事長』!!! 　 2025-06-02　恭賀洪經勝醫檢師當選『第17屆台北市醫檢師公會理事長』!!! 　 2025-05-15　✪114年度實驗室開發檢測之資深暨新進實驗室人員訓練課程✪請參閱最新消息公告！　 2025-04-16　恭賀黃碧標醫檢師當選『第16屆臺中市大臺中醫檢師公會理事長』!!! 　 2023-07-01　會員如有權益相關問題及對本會有任何建議或意見回饋，歡迎利用電子信箱或致電本會，謝謝您!! 　 2015-02-02　醫事檢驗師宣誓誓詞，誓詞內容請至文件下載區查閱，並請協助推廣，謝謝！　

歷年稿件內容

*類別：
* 姓名：	林聰義
投稿種類：
*中文投稿標題：	Personalized medicine and the HLA-B*1502 pharmacogenomic testing
*中文作者姓名列：
*中文服務單位：
*英文投稿標題：
*英文作者姓名列：
*英文服務單位：
* 投稿摘要：	Personalized medicine may provide the right drug, at the right dose, on the right time and for the right person. The understanding of the correlation between an individual patient's genotype and h is response to the drug is of prime importance. Carbamazepine is a drug commonly prescribed for the treatment of seizures, it can cause a variety of hypersensitivity reactions, including Stevens–Johnson syndrome and toxic epidermal necrolysis, both having an impact of high mortality and morbidity. There is a strong association in Han Chinese between the human leukocyte antigen HLA–B1502, and Stevens–Johnson syndrome/toxic epidermal necrolysis induced by carbamazepine (Wen-Hung Chung et al). We have done 53 cases of HLA-B1502 testing from April 2011 till now, all these patients are suffering from a number of maladies : epilepsy 9.4% (5/53), trigeminal neuralgia 28.3% (15/53), bipolar affective disorder 52.8% (28/53), primary gloss pharyngeal neuralgia 1.9% (1/53), maladies under investigation 7.6% (4/53). Among these 53 testing, 7.6% (4/53) patients are positive in HLA-B1502 testing, two patients suffering from trigeminal neuralgia and the other two patients suffering from bipolar affective disorder. All four patients with positive result never took carbamazepine before, and show no adverse drug reaction toward replacement treatment of quetiapine, oxcarbazepine and flunitrazepam. Patients with negative HLA–B1502 results show no adverse drug reaction after carbamazepine treatment. The outcome reveals that the specificity and the efficacy of HLA-B1502 testing is awesome in preventing severe adverse drug reaction of carbamazepine, as expected. Physician’s understanding of the association between HLA–B1502 and Stevens–Johnson syndrome/toxic epidermal necrolysis before the prescribing of carbamazepine is very important. A computer-assisted early alarm system to remind the physician to check patient’s HLA-B*1502 status before the prescribing of carbamazepine is a mandatory step to assure patient safety and in addition, to get rid of lawsuits against physician.
*關鍵字1 ：	Pharmacogenomics
*關鍵字2 ：	HLA-B*1502
*關鍵字3 ：	Stevens–Johnson syndrome
*關鍵字4 ：
*關鍵字5 ：
* 服務機關：
* 第一作者：	楊佩芝
* 身分字號：	*****75822
其他投稿作者：
身分字號：
其他投稿作者：
身分字號：
其他投稿作者：
身分字號：
其他投稿作者：
身分字號：
其他投稿作者：
身分字號：
其他投稿作者：
身分字號：
其他投稿作者：
身分字號：
上傳稿件檔：	開啟檔案
審查委員意見：	"無意見"
審查委員意見：	OK
主任委員意見：